CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers

Craig McKenzie¹, Nirupama Varese², Pei Aui¹, Bruce Wines³, P Hogarth³, Francis Thien⁴, Mark Hew⁵, Jennifer Rolland⁶, Robyn O’Hehir⁵, and Menno van Zelm⁷

¹Monash University
²Alfred Health
³Burnet Institute
⁴Eastern Health and Monash University, Box Hill Hospital
⁵Alfred Hospital
⁶The Alfred Hospital
⁷Monash University

November 20, 2020

Abstract

Background: Diagnostic tests for allergy rely on detecting allergen-specific IgE. Component-resolved diagnostics incorporate multiple defined allergen components to improve the quality of diagnosis and patient care. Objective: To develop a new approach for determining sensitization to specific allergen components that utilizes fluorescent protein tetramers for direct staining of IgE on blood basophils by flow cytometry. Methods: Recombinant forms of Lol p 1 and Lol p 5 proteins from ryegrass pollen (RGP) and Api m 1 from honeybee venom (BV) were produced, biotinylated and tetramerized with streptavidin-fluorophore conjugates. Blood samples from 50 RGP-allergic, 41 BV-allergic and 26 controls were incubated with fluorescent protein tetramers for flow cytometric evaluation of basophil allergen binding and activation. Results: Allergen tetramers bound to and activated basophils from relevant allergic patients but not controls. Direct fluorescence staining of Api m 1 and Lol p 1 tetramers had greater positive predictive values than basophil activation for BV and RGP allergy, respectively, as defined with receiver operator characteristics (ROC) curves. Staining intensities of allergen tetramers correlated with allergen-specific IgE levels in serum. Inclusion of multiple allergens coupled with distinct fluorochromes in a single tube assay enabled rapid detection of sensitization to both Lol p 1 and Lol p 5 in RGP-allergic patients and discriminated between controls, BV-allergic and RGP-allergic patients. Conclusion: Our novel flow cytometric assay, termed CytoBas, enables rapid and reliable detection of clinically relevant allergic sensitization. The intensity of fluorescent allergen tetramer staining of basophils has a high positive predictive value for disease and the assay can be multiplexed for a component-resolved and differential diagnostic test for allergy.

CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers

Craig I. McKenzie¹, Nirupama Varese¹,², Pei Mun Aui¹, Bruce D. Wines¹,³,⁴, P. Mark Hogarth¹,³,⁴, Francis Thien⁵, Mark Hew⁶,⁷, Jennifer M. Rolland¹,², Robyn E. O’Hehir¹,²,⁷, Menno C. van Zelm¹,⁷

¹ Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia;
² Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University,
Melbourne, VIC, Australia;
3 Immune Therapies Group, Burnet Institute, Melbourne, Australia;
4 Department of Pathology, The University of Melbourne, Parkville, VIC, Australia;
5 Respiratory Medicine, Eastern Health, Box Hill and Monash University, Melbourne, VIC, Australia;
6 School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia;
7 Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, VIC, Australia.

Corresponding author: Menno C. van Zelm, PhD
Department of Immunology and Pathology
Central Clinical School, Monash University
89 Commercial Road, Melbourne VIC 3004, Australia
Email: menno.vanzelm@monash.edu

Funding Information
The studies were supported financially by a NHMRC Senior Research Fellowship GNT1117687 to MCvZ, a Central Clinical School Early Career Fellowship to CIM and by NHMRC project grant GNT145303 to PMH, REO’H, BDW.

Highlights
- Fluorescent recombinant allergen tetramers specifically bind to and activate basophils from patients allergic to bee venom (Api m 1) and ryegrass pollen (Lol p 1 and Lol p 5).
- Staining intensities of recombinant Api m 1 and Lol p 1 tetramers have greater positive predictive values for allergy than basophil activation.
- A single flow cytometric stain with multiple allergen tetramers can be applied as a rapid component-resolved and differential diagnostic test for allergy.

Key words
Component-resolved diagnostics, allergen tetramers, basophils, surface IgE, flow cytometry

Abbreviations: AIT, allergen-specific immunotherapy; Anti-hIgE, anti-human IgE; AU, arbitrary units; AUC, area under the curve; BAT, basophil activation test; BV, bee venom; MFI, median fluorescence intensity; PBMC, peripheral blood mononuclear cells; RGP: ryegrass pollen; ROC: receiver operator characteristics; SPT: skin prick test

ABSTRACT

Background: Diagnostic tests for allergy rely on detecting allergen-specific IgE. Component-resolved diagnostics incorporate multiple defined allergen components to improve the quality of diagnosis and patient care.

Objective: To develop a new approach for determining sensitization to specific allergen components that utilizes fluorescent protein tetramers for direct staining of IgE on blood basophils by flow cytometry.

Methods: Recombinant forms of Lol p 1 and Lol p 5 proteins from ryegrass pollen (RGP) and Api m 1 from honeybee venom (BV) were produced, biotinylated and tetramerized with streptavidin-fluorophore conjugates. Blood samples from 50 RGP-allergic, 41 BV-allergic and 26 controls were incubated with fluorescent protein tetramers for flow cytometric evaluation of basophil allergen binding and activation.

Results: Allergen tetramers bound to and activated basophils from relevant allergic patients but not controls. Direct fluorescence staining of Api m 1 and Lol p 1 tetramers had greater positive predictive values
than basophil activation for BV and RGP allergy, respectively, as defined with receiver operator characteristics (ROC) curves. Staining intensities of allergen tetramers correlated with allergen-specific IgE levels in serum. Inclusion of multiple allergens coupled with distinct fluorochromes in a single tube assay enabled rapid detection of sensitization to both Lol p 1 and Lol p 5 in RGP-allergic patients and discriminated between controls, BV-allergic and RGP-allergic patients.

**Conclusion:** Our novel flow cytometric assay, termed CytoBas, enables rapid and reliable detection of clinically relevant allergic sensitization. The intensity of fluorescent allergen tetramer staining of basophils has a high positive predictive value for disease and the assay can be multiplexed for a component-resolved and differential diagnostic test for allergy.

**INTRODUCTION**

Diagnosis of IgE-mediated allergy is based on the patient’s clinical symptoms and medical history, confirmed with laboratory tests.\(^1\) The latter are becoming increasingly important for patient management, as well as for selection for and monitoring of allergen-specific immunotherapy (AIT). Currently, skin prick testing (SPT) and detection of serum specific IgE using allergen extracts are standard methods to differentiate sensitized from non-sensitized individuals.\(^2\) While serum specific IgE detection is highly sensitive, the use of allergen extracts can yield positive results due to recognition by cross-reactive antibodies of components that are not the drivers of disease.\(^3\)-\(^8\)

Basophil activation tests (BAT), i.e. *in vitro* exposure of blood basophils to increasing doses of allergen,\(^9\) have the advantage of detecting functional IgE that on binding allergen, can directly result in degranulation and development of allergic symptoms.\(^10\) IgE bound to FcεRI is cross-linked by allergen and triggers signaling and basophil degranulation. Resultant surface expression of CD63 is a reliable indicator of the sensitivity and reactivity of basophils to an allergen.\(^9\) BAT is a functional assay with advantages over serology for specific IgE in that it can more accurately diagnose allergies and monitor responses to immunotherapy.\(^10\) However, BAT requires *in vitro* stimulation of multiple blood samples with serial dilutions of allergen as well as positive and negative controls, which has thus far hampered large-scale diagnostic implementation.\(^8\)

A different approach for detection of relevant allergen sensitization is the use of molecular allergen components that are either purified from allergen extracts or produced recombinantly. Detection of IgE reactivity to major allergen components has the potential to be highly sensitive with high specificity through omission of cross-reactive components that are less relevant for disease.\(^11\)-\(^13\) For example sensitization to Der p 1 and/or Der p 2, the major house dust mite (HDM) allergens, is a better positive predictor for HDM-driven asthma than whole HDM extract.\(^14,15\) Furthermore, sensitization to Ara h 2, a major peanut allergen, is more specific for systemic allergic responses than whole peanut extract.\(^16,17\) Consequently, sensitization patterns to molecular allergen components can be relevant for patient management and treatment.\(^18,19\) The major ryegrass pollen (RGP) allergens Lol p 1 and Lol p 5 are each detected by serum IgE of 80-90% of RGP-allergic individuals.\(^20\)-\(^23\) Importantly, Lol p 5 sensitization is associated with a higher risk of thunderstorm asthma,\(^24,25\) and would be a potential indicator for AIT.\(^26\)

The major allergen component of BV is Api m 1, whereby 78-90% of people allergic to BV have Api m 1-specific IgE in serum.\(^27,28\) BV extracts used in AIT for BV allergy typically contain Api m 1 but may lack another key major allergen associated with systemic reactions, Api m 10. Patients with high sensitization to Api m 10 will not benefit from treatment with such currently-available SCIT preparations, highlighting the importance of resolving both disease and treatment at the component level for accurate prescription of AIT.\(^5,19,29\)

Despite our understanding of these allergen components, the use of component-resolved diagnostics has not become routine or standard practice. At present, these may be applied as follow-up tests to confirm or refute an initial test using whole allergen extract.\(^17\) Ideally, a single laboratory test would enable differential detection of allergen sensitization and stratification of patients into clinical risk groups. This would constitute a multiplex assay that can incorporate a relevant set of allergen components for e.g. aeroallergens, food allergens or stinging insect allergens.
We have generated fluorescently-labelled tetramers of the major allergen components Api m 1, Lol p 1 and Lol p 5 to explore component-resolved diagnostics using direct staining of blood basophils in a single test - CytoBas. Application of these reagents in flow cytometry showed specific binding to basophils of sensitized patients, with a higher positive predictive value for allergy than BAT. Fluorescence intensity of allergen tetramers on the surface of basophils correlated with titers of allergen-specific IgE in serum. Importantly, by using different fluorochromes, binding of multiple allergen components can be assessed simultaneously, enabling a differential and component-resolved allergy diagnostic in a single flow cytometric assay and without the need for cell stimulation.

METHODS

2.1 Study participants

Allergic subjects were recruited from the Allergy Clinics of The Alfred and Box Hill Hospitals Melbourne, Victoria, Australia (Alfred Ethics Committee projects 509/11 and 514/13). Forty-one BV-allergic patients (18-68 years; 32% female) were diagnosed on the basis of a systemic allergic response to a bee sting and serum BV-specific IgE of >0.35 kU/L (ImmunoCAP, Phadia, Uppsala, Sweden). Fifty RGP-allergic patients (18-65 years; 52% female) were included with moderate to severe seasonal allergic rhinitis with or without asthma, and serum RGP-specific IgE of >0.35 kU/L (ImmunoCAP). Blood from RGP-allergic subjects was collected in April/May outside of the Australian grass pollen season (Sept-Dec). Twenty-six control subjects (22-58 years; 50% female) had no clinical history of BV and/or RGP allergy as appropriate for the assay, and no detectable specific IgE to the relevant allergen (Monash University project 2016-0289). Exclusion criteria were immunodeficiency, AIT within the last five years, and treatment with continuous oral corticosteroids and/or β-blockers. The use of symptomatic medications (incl. antihistamines and topical corticosteroids) for allergic rhinitis was permitted. The study was conducted according to the principles of the Declaration of Helsinki, and written informed consent from each participant was obtained prior to inclusion.

2.2 Blood sampling and ELISA

Heparinized blood samples were processed within 24 hours of collection for basophil activation, PBMC and serum isolation and storage. Serum RGP-specific-IgE and BV-specific IgE levels were measured by ImmunoCAP using allergen extracts as per manufacturer’s instructions at the Alfred Pathology Services (Alfred Hospital, Melbourne, Australia). Serum Lol p 1- and Lol p 5-specific IgE were measured by a semi-quantitative in-house ELISA as described previously. Briefly, ELISA plate wells were coated with recombinant monomeric, non-biotinylated Lol p 1 (MyBiosource, San Diego, CA, US) or Lol p 5 (see below), blocked with 5% skim milk powder in PBS and incubated with serial dilutions of serum samples. Separate wells were incubated with a range of concentrations of purified recombinant human IgE (clone AbD18705; Bio-Rad, Puchheim, Germany) to generate a standard curve for quantification of IgE in serum. Bound IgE was detected using polyclonal rabbit anti-hIgE (Agilent, Santa Clara, CA, US) followed by polyclonal goat anti-rabbit HRP (Promega, Madison, WI, US). ELISA were developed using TMB (Thermo Fisher Scientific, Waltham, MA, US) before the reaction was stopped with 1M HCl and absorbance measured at OD 450 nm on a Multiskan Microplate Spectrophotometer (Thermo Fisher Scientific). Wells without allergens were used to determine background values that were subtracted from allergen-specific IgE values and results are expressed in arbitrary units (AU).

2.3 Recombinant allergen production

For recombinant protein production, the protein sequences of Api m 1.0101, Lol p 1.0101 and Lol p 5.0101 were obtained from the Allergen Nomenclature website (allergen.org). All three constructs were generated with the Api m 1 N-terminal leader sequence for secretion, as well as a 6-His tag for purification and a BirA tag for biotinylation (Figure 1A ). To prevent unwanted effects of catalytic activity, mutations were introduced in Api m 1 (H67Q) and Lol p 1 (H104V), as published previously. All constructs were codon-optimized for Spodoptera frugiperda and cloned into the pFastBac vector (Thermo Fisher Scientific), prior to incorporation into a Bacmid for baculovirus production. Bacmids were transfected into Sf21 cells, which were subsequently cultured at 27°C. Supernatants from infected Sf21 cultures were clarified by centrifugation and the 6-His
tagged proteins were purified through retention on a cobalt column. Supernatants were gravity-fed through a 25 ml column packed with 4 ml Talon NTA-cobalt-agarose beads (Clontech, Mountain View, CA, US). Beads were washed with PBS and allergens eluted with PBS, pH 8.5, containing 200 mM imidazole. Eluate was dialyzed against 10 mM TRIS, pH 7.5. The purified recombinant proteins were incubated overnight at RT with BirA enzyme for targeted biotinylation (2.5 μg/ml BirA in 10 mM TRIS containing 62.5 mM Bicine-HCl, 12.5 mM ATP, 12.5 mM MgOAc, 62.5 μM D-biotin). Following subsequent dialysis against PBS, tetramerization was performed with fluorochrome-conjugated streptavidin (PE, APC and BV711 conjugates; all from BD Biosciences, San Jose, CA, US) at a 4:1 molar ratio of allergen:streptavidin.

### 2.4 Western blotting

Baculovirus-infected Sf21 supernatants were mixed with 6X non-reducing buffer (0.1 M Tris-HCl, pH 6.8, 0.2% bromophenol blue, and 20% glycerol). Protein samples were then loaded onto 4-15% Mini-PROTEAN® TGX Stain-Free gels (Bio-Rad) and separated at 200V for 30 mins. Proteins were transferred onto PVDF membranes (Bio-Rad) using the Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were probed with mouse anti-His (clone 27471001, GE Healthcare, Chicago, IL, US) followed by goat anti-mouse IgG HRP (clone NA9310N; Cell Signaling Technology, Danvers, MA, US). PVDF membranes were developed using Amersham ECL Western Blotting Detection Reagent (GE Healthcare) and chemiluminescence was detected using a ChemiDoc Imager (Bio-Rad).

### 2.5 Basophil activation test

To prime circulating basophils, whole blood was incubated for 10 mins at 37°C in stimulation buffer (Hepes 20 mM, NaCl 133 mM, KCl 5 mM, CaCl₂ 7 mM, CaCl₃ 3.5 mM, BSA 1 mg/ml, rIL-3 2 ng/ml, Heparin 20 μl/ml, pH 7.4). Basophils were incubated with RGP extract (0.001 – 1 μg/ml; Stallergenes Greer, London, UK), BV extract (0.01 – 1 μg/ml; HollisterStier Allergy, Spokane, WA, US), fluorescent allergen tetramers (0.01, 0.1, 1 μg/ml) or streptavidin conjugate only (1 μg/ml) for 20 mins at 37°C. In parallel, stimulations with rabbit anti-human IgE (0.1 – 10 μg/ml; Agilent) or fMLP (8 nM; Sigma, St. Louis, MO, US) were performed to control for FcεRI-dependent and FcεRI-independent degranulation, respectively. Activation was stopped by incubating on ice for 5 mins. Cells were washed with cold wash buffer (Hepes 20 mM, NaCl 133 mM, KCl 5mM, EDTA 0.27 mM, pH 7.3) prior to flow cytometry.

### 2.6 Flow cytometry

Direct staining of thawed PBMC was performed with fluorescent allergen tetramers and CD123-BV605 (6H6; BioLegend, San Diego, CA, US) and IgE-FITC (polyclonal, Thermo Fisher Scientific) for 15 min at RT in the dark. Flow cytometry on activated samples for the BAT was performed with CD123-BV605, CD63-PE (H5C6; BD Biosciences) and either IgE-FITC or HLA-DR-APC (L243; BioLegend). 7AAD was added to samples immediately prior to flow cytometry to distinguish between live and dead cells (Suppl Fig 1). All flow cytometry was performed across two instruments (4-laser BD LSRII and 5-laser BD LSRFortessa X-20) with a nearly identical set-up for the shared 4 lasers. Instrument set-up and calibration was performed using standardized EuroFlow SOPs as described in detail previously. Statistical analysis

### 2.7 Statistical analysis

All flow cytometry data were analyzed with FACS DIVA v8.0.1 (BD Biosciences) and FlowJo v10 software packages (FlowJo LLC, Ashland, OR, US). Statistical analyses were performed using Graphpad Prism (v8.4.1): the non-parametric Wilcoxon signed rank test for paired data and the non-parametric Mann-Whitney U-test for unpaired data. Receiver operating characteristic (ROC) curves were used to determine specificity and sensitivity of BAT or CytoBas for distinguishing between control and allergic patients. For all tests, p<0.05 was considered significant.

### RESULTS

#### 3.1 Design and production of recombinant allergen tetramers for CytoBas
Immunodominant allergen components of BV and RGP were selected for generation of recombinant allergen tetramers (Api m 1, Lol p 1 and Lol p 5).20-22,27,28 The full-length Api m 1 protein was produced with the native leader sequence, and C-terminal 6-His and BirA tags for purification and biotinylation (Figure 1A). The construct contained a H67Q mutation to prevent catalytic activity without affecting IgE reactivity.34 Similarly, the Lol p 1 and Lol p 5 constructs were generated with the Api m 1 leader sequence to target these for secretion. Lol p 1 catalytic activity was abolished by a H104V mutation.35 Purified allergens were probed by Western blot using an anti-6-His antibody and detected at expected sizes with typical diversity in glycosylation density (Figure 1B). Recombinant allergens were biotinylated and tetramerized with a streptavidin-APC conjugate to generate Api m 1, Lol p 1 and Lol p 5 tetramers.

The ability of allergen tetramers to detect specific IgE on basophils using flow cytometry was assessed using whole blood samples of allergic patients and controls. Following 15 min incubation with the relevant allergen tetramer and mAbs, binding of allergen to CD123+ IgE+ basophils was examined (Figure 1C). The Api m 1 tetramer ([Api m 1]4-APC) specifically stained basophils from a BV-allergic individual and not a control (Figure 1D). Similarly, [Lol p 1]4-APC and [Lol p 5]4-APC each positively stained basophils from an RGP-allergic patient, and not a control. Thus, these recombinant allergen tetramers can be used to detect allergen sensitization by binding specific IgE on the surface of basophils using flow cytometry (CytoBas).

3.2 Recombinant Api m 1 tetramer staining detects functional allergic sensitization to bee venom

To determine whether positive staining of basophils with [Api m 1]4 indicates functional allergic sensitization to BV, blood samples from 41 BV-allergic patients and 24 controls were incubated for 20 min at 37°C with increasing amounts of [Api m 1]4-APC or, as a control, 1 μg/ml streptavidin-APC. Samples were then stained with mAbs to detect basophils, and within this population, expression of CD63 was assessed as a marker of activation and degranulation. There was a dose-dependent increase in staining of basophils following incubation with [Api m 1]4-APC in all 41 patients with BV allergy (Figure 2A). In contrast, there was no increase in staining with [Api m 1]4-APC over the streptavidin-APC reagent on basophils from the control cohort (Figure 2A). Thus, the specific binding of allergen tetramer to basophils of BV-allergic patient was accompanied by a dose-dependent increase in the frequency of basophils with surface expression of CD63 (Figure 2B). The frequency of CD63+ basophils following incubation with [Api m 1]4-APC was negligible for control subjects. Similarly, parallel incubation of blood samples with BV extract resulted in CD63 expression only on basophils of BV-allergic patients and not controls (Figure 2C). Basophils from all BV-allergic and control subjects expressed surface CD63 following incubation with positive controls anti-IgE and/or fMLP, indicating that basophils in all blood samples were functionally capable of degranulation (Suppl. Figure 2A, B). Thus, the CytoBas approach with [Api m 1]4 has the capacity to detect relevant and functional allergic sensitization to BV.

3.3 Recombinant Lol p 1 tetramer staining detects functional allergic sensitization to ryegrass pollen

The ability of [Lol p 1]4 to detect functional allergen sensitization was examined using blood samples from 50 RGP-allergic patients and 20 controls. Following incubation with increasing amounts of [Lol p 1]4-APC or control streptavidin-APC, basophils of patients and controls were examined for allergen binding (Figure 3A) and activation (CD63 positivity; Figure 3B). Incubation with [Lol p 1]4-APC resulted in a dose-dependent increase in signal observed in all 50 patients with RGP allergy (Figure 3A). The increase in staining intensity indicated functional allergen binding, as this was accompanied by increased frequencies of CD63+ basophils in the patient samples (Figure 3B). In contrast, basophils in the control cohort did not show any increase of allergen staining over the strep-APC reagent (Figure 3A). There was negligible CD63 expression on basophils of controls. Similarly, parallel incubations of blood with RGP extract only resulted in significant CD63 expression on basophils of patients and not controls (Figure 3C). Activation by anti-IgE and/or fMLP resulted in increased CD63 expression on basophils from all patients and controls, indicating that these cells were functionally capable of degranulation (Suppl. Figure 3A, B). Thus, as for BV allergy, the CytoBas approach can be utilized for RGP allergy with a major recombinant allergen
component, Lol p 1, to detect relevant and functional allergic sensitization.

### 3.4 Allergen tetramers bind the total basophil population in sensitized individuals irrespective of activation

Conventional understanding of basophils capturing polyclonal IgE via their FcεRI suggests that all basophils of an allergic patient have the potential to bind IgE with specificity to an allergen molecule. However, typically only a fraction of the basophils will degranulate and express CD63 following stimulation with that allergen. To examine whether the CD63+ basophils differed from CD63− basophils in terms of allergen binding specificity and capability, the staining intensities of the allergen tetramers were re-examined following stratification of basophils based on CD63 expression after in vitro stimulation (Figure 2B, 3B). Both the CD63− and the CD63+ basophils from all 41 BV-allergic individuals showed strong staining with [Api m 1]4-APC as compared to streptavidin-APC. Importantly, the CD63− and CD63+ fractions bound similar amounts of Api m 1 (Suppl. Figure 4A). Similarly, [Lol p 1]4-APC showed high degrees of binding to both CD63+ and CD63− basophils from the 50 RGP-allergic individuals, albeit with slightly but significantly lower levels on the CD63− subset (Suppl. Figure 4B). Thus, in sensitized individuals, all basophils may have surface bound allergen-specific IgE, but not all will degranulate upon binding to allergen.

### 3.5 Greater diagnostic ability of basophil staining than activation with recombinant allergen tetramers

The BV-allergic and RGP-allergic individuals in this study were diagnosed based on their clinical history, SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards. To compare the predictive values of the BAT and CytoBas for allergy, ROC of their outcomes were determined. For each individual, the highest SPT and/or allergen-specific serum IgE, as per clinical standards.
patient only bound [Api m 1](Figure 6A). The MFI of staining on basophils for each of the three allergens correlated strongly with serum allergen-specific IgE (each $p<0.0001$; Figure 6B-D). This is in contrast to the frequency of activated (CD63+) basophils stimulated with Api m 1 and Lol p 1 tetramers, which showed a poorer correlation with Api m 1-specific IgE ($r^2 = 0.03561, p = 0.2436$) or Lol p 1-specific IgE ($r^2 = 0.1313, p = 0.0114$), respectively. The CytoBas technique therefore reflects allergen-specific IgE titers in serum with greater accuracy than basophil activation. Taken together, these data demonstrate that a single flow cytometric assay with multiple allergen tetramers can provide a rapid component-resolved and differential diagnostic test for allergy.

**DISCUSSION**

We describe here a novel methodology for a component-resolved diagnostic test for allergy using multiplex flow cytometry involving direct staining of basophils with recombinant allergen tetramers – CytoBas. This flow cytometric approach enabled rapid detection with high sensitivity and specificity of BV allergy with Api m 1 and of RGP allergy with Lol p 1. Combined staining of Api m 1 and Lol p 1 reliably enabled differential detection of allergen sensitization, and inclusion of both Lol p 1 and Lol p 5 facilitated quantification of the relative sensitization to distinct components of RGP in a single-tube test. The combination of multiple allergens from a single species provided complete discrimination between RGP-allergic patients and controls, highlighting the utility of multiplex CytoBas in diagnosing allergies that exhibit sensitization to multiple allergen components.

The allergens in our study were recombinantly-produced proteins. This approach facilitates the introduction of mutations that disrupted enzymatic function and the addition of protein tags for biotinylation and purification. Api m 1, Lol p 1 and Lol p 5 contain glycan structures. Because the glycosylation patterns of proteins in invertebrates and plants are more similar to each other and differ strongly from mammals, we here produced their recombinant forms in the Sf21 insect cell line. Similar to a previous report utilizing Sf9 cells, we obtained two main glycosylated products of the recombinant Api m 1, fitting with the native paucimannosidic type of glycosylation. Both recombinant RGP allergens had greater sizes than predicted for non-glycosylated variants, and showed high sensitivity and specificity for detection of RGP allergy. The high sensitivity and specificity of our recombinant allergen components for confirmation of BV and RGP allergies indicates that our approach preserves the major epitopes for IgE binding. The fact that invertebrate- and plant-derived proteins can be generated as such in an insect cell line, as confirmed here, demonstrates the potential to apply our CytoBas assay for detection of sensitization to a huge diversity of food-, aero- and stinging insect-derived allergens.

Our CytoBas study exploits the concept that basophils present high levels of IgE on their surface through FcεRI binding, and that this IgE is polyclonal and reflective of the specificities produced in an individual. This is the same concept that is utilized for BAT, even though there is typically a fraction of cells that does not degranulate and express CD63 after allergen stimulation. Our direct staining approach showed that in the case of allergen-sensitization, all basophils become positive with the population showing a Gaussian distribution of staining intensity. The median staining intensities correlated strongly with allergen-specific serum IgE levels, and so could be used in a similar manner for quantitating the response. Furthermore, the polyclonal nature of IgE on basophils enabled detection of multiple specificities on the total population in a single test.

RGP-allergic patients with Lol p 1 and Lol p 5 co-sensitization showed double-positive basophil populations. This is in contrast to a recent study where distinct basophil subsets were positive for either recombinant Api m 1 or recombinant Api m 2 conjugated to fluorescent quantum dots (Qdots). The reason for this difference is unclear, as it is unlikely that within an individual, distinct basophil populations will present unique allergen specificities. Therefore, it will be important for applications of multicolor flow cytometry to incorporate appropriate controls and establish standardized instrument settings for reproducible and robust measurements.

Another novel observation from this study is that degranulated basophils (CD63+) bind allergen tetramers
with similar intensity as basophils that have not degranulated (CD63\(^{-}\)) in the same assay. Typically, the proportion of basophils that degranulate in a BAT forms a bell-shaped curve with increasing concentrations of allergen. The maximum frequency of CD63\(^{+}\) cells will differ between individuals, and the dose-response curve is thought to be affected by the affinity of IgE to the antigen, the density of the epitope-specific IgE on the cell surface, and the functional capacity of the basophil itself.\(^{46-48}\) Our observation argues against differences in basophils from the same individual with regards to IgE affinity or density of epitope-specific IgE. Rather, intrinsic characteristics of the basophil, e.g. signaling threshold, degranulation capacity and maturity, could underlie the differences between those cells that do degranulate and the fraction of cells that does not.

Our allergens were tetramerized using streptavidin-fluorophore conjugates. A previous study has reported that activated basophils may have the capacity to bind streptavidin via positively-charged molecules that are expressed on the basophil surface upon degranulation.\(^{49}\) This could potentially lead to non-specific binding of allergen tetramers to degranulated basophils. In our experiments, we did not observe such an effect and the fluorescence intensities of our allergen tetramers were similar between basophils that had degranulated and those that had not. Still, it is recommended for multiparameter analysis of allergen binding to perform incubations for staining at room temperature or even at \(4^\circ\)C to minimize the potential for activation and degranulation of basophils that might mediate non-specific binding of streptavidin.

Using a multiparameter staining approach with three allergen components, we demonstrated that CytoBas enabled detection of sensitization to multiple components of the same allergen (RGP; Lol p 1 and Lol p 5) as well as differential sensitization to distinct allergens (BV; Api m 1 vs RGP; Lol p 1 and/or Lol p 5). This differential and component-resolved analysis through staining of basophils has several advantages over BAT: 1) The CytoBas assay only requires direct staining with allergen tetramers and mAbs without the need for \textit{in vitro} stimulation, making it less dependent on maintaining basophil function \textit{ex vivo}, less labor intensive and easier to standardize; 2) CytoBas has the potential for a single staining with multiplex detection of distinct allergen components, rather than the need for multiple (7-10) independent conditions for titration of each allergen in the BAT; 3) For BV and RGP allergy, two distinct allergic diseases, CytoBas with Api m 1 and Lol p 1 distinguished between allergic patients and controls with greater sensitivity and specificity than the BAT; 4) Basophil staining with recombinant allergen tetramers is possible on fresh whole blood, fresh PBMC and cryopreserved PBMC enabling more flexibility for transport or batch analysis of clinical samples than is currently possible with the BAT, which requires processing of fresh blood within 24 hrs.\(^{50}\) A current limitation is the availability of recombinant allergens with the correct modifications for tetramerization with fluorescently-labeled streptavidin. However, with the potential for use of insect cells to generate plant and invertebrate proteins, and the vast experience with recombinant proteins in serology-based component resolved diagnostics, this will only be a temporary hurdle.

CytoBas with Lol p 1 tetramers exhibited greater sensitivity and specificity than previously reported for clinical history, SPT and allergen-specific IgE in allergic rhinitis patients sensitized to pollen aeroallergens.\(^{51}\) With the potential for multiplex analysis in a single assay, CytoBas has the potential to compete with serology-based IgE tests. Theoretically, a combination of 2-4 major allergen components could be applied to a) detect allergen reactivity in a highly sensitive manner; and b) detect specific sensitization and risk of systemic response, without the need for repeat tests that are currently recommended for e.g. peanut allergy.\(^{17}\) In practice, the composition of a CytoBas assay and its performance will need to be tested and compared to the standard diagnostic workflow for each diagnostic process. The availability of high-end clinical cytometers that allow 10 or more components to be multiplexed in one assay provides the potential for CytoBas to provide a rapid component-resolved diagnostic test for allergy whilst avoiding allergen challenge.

ACKNOWLEDGMENTS

The authors gratefully acknowledge Kirsten Deckert, Sara Bulen, Anita Hazard, Monique Dols and Anna Mackay for collection of clinical data and blood samples from patients, and Adam Nelson and Rosalyn Cao for technical support. We thank Dr. Lucy Sullivan, Ms Sandra Verschoor and Prof Joseph Trapani for sharing of reagents, and the AMREP Flow Cytometry Core Facility team for technical assistance.
CONFLICT OF INTEREST

MCvZ, ROH and PMH are inventors on a patent application related to this work. All the other authors declare that they have no relevant conflicts of interest.

ORCID

Craig I. McKenzie https://orcid.org/0000-0001-7070-620X
Nirupama Varese https://orcid.org/0000-0001-9074-3710
Pei M. Aui https://orcid.org/0000-0002-2314-9989
Bruce D. Wines https://orcid.org/0000-0002-4108-375X
P. Mark Hogarth https://orcid.org/0000-0002-0360-7890
Francis Thien https://orcid.org/0000-0003-0925-6566
Mark Hew https://orcid.org/0000-0002-7498-0000
Jennifer M. Rolland https://orcid.org/0000-0002-7891-983X
Robyn E. O’Hehir https://orcid.org/0000-0002-3489-7595
Menno C. van Zelm https://orcid.org/0000-0003-4161-1919

REFERENCES

1. van Zelm MC, McKenzie CI, Varese N, Rolland JM, O’Hehir RE. Recent developments and highlights in immune monitoring of allergen immunotherapy. Allergy. 2019;74(12):2342-2354.
2. Valenta R, Karaulov A, Niederberger V, et al. Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(6):1845-1855.e1842.
3. Carnés J, Iraola V, Cho SH, Esch RE. Mite allergen extracts and clinical practice. Annals of Allergy, Asthma & Immunology. 2017;118(3):249-256.
4. Codina R, Lockey RF. Pollen used to produce allergen extracts. Annals of Allergy, Asthma & Immunology. 2017;118(2):148-153.
5. Frick M, Fischer J, Helbling A, et al. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy. Journal of Allergy and Clinical Immunology. 2016;138(6):1663-1671.e1669.
6. Rolland JM, Varese NP, Abramovitch JB, et al. Effect of Heat Processing on IgE Reactivity and Cross-Reactivity of Tropomyosin and Other Allergens of Asia-Pacific Mollusc Species: Identification of Novel Sydney Rock Oyster Tropomyosin Sac g 1. Molecular Nutrition & Food Research. 2018;62(14):1800148.
7. Vieths S, Hoffmann A, Holzhauser T, Muller U, Reindl J, Haustein D. Factors influencing the quality of food extracts for in vitro and in vivo diagnosis. Allergy. 1998;53(46 Suppl):65-71.
8. Uyttebroek AP, Sabato V, Faber MA, et al. Basophil activation tests: time for a reconsideration. Expert Review of Clinical Immunology. 2014;10(10):1325-1335.
9. MacGlashan DW. Basophil activation testing. Journal of Allergy and Clinical Immunology. 2013;132(4):777-787.
10. Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015;70(11):1393-1405.
11. Bilò MB, Ollert M, Blank S. The role of component-resolved diagnosis in Hymenoptera venom allergy. *Current Opinion in Allergy and Clinical Immunology*. 2019;19(6).

12. Luengo O, Cardona V. Component resolved diagnosis: when should it be used? *Clinical and Translational Allergy*. 2014;4(1):28.

13. Stringari G, Tripodi S, Caffarelli C, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. *Journal of Allergy and Clinical Immunology*. 2014;134(1):75-81.e72.

14. Huang HJ, Resch-Marat Y, Rodríguez-Dominguez A, et al. Underestimation of house dust mite-specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs. *J Allergy Clin Immunol*. 2018;142(5):1656-1659.e1659.

15. Huang Y, Wang C, Lin X, et al. Association between component-resolved diagnosis of house dust mite and efficacy of allergen immunotherapy in allergic rhinitis patients. *Clin Transl Allergy*. 2019;9:64.

16. Dang TD, Tung M, Choo S, et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. *J Allergy Clin Immunol*. 2012;129(4):1056-1063.

17. Lieberman JA, Glauermann S, Batelson S, Borres MP, Sampson HA, Nilsson C. The utility of peanut components in the diagnosis of IgE-mediated peanut allergy among distinct populations. *J Allergy Clin Immunol Pract*. 2013;1(1):75-82.

18. Treudler R, Simon JC. Overview of component resolved diagnostics. *Curr Allergy Asthma Rep*. 2013;13(1):110-117.

19. Köhler J, Blank S, Müller S, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. *Journal of Allergy and Clinical Immunology*. 2014;133(5):1383-1389.e1386.

20. Matthiesen F, Löwenstein H. Group V allergens in grass pollens. II. Investigation of group V allergens in pollens from 10 grasses. *Clinical & Experimental Allergy*. 1991;21(3):309-320.

21. Ong EK, Knox RB, Singh MB. Mapping of the antigenic and allergenic epitopes of Lol p VB using gene fragmentation. *Molecular Immunology*. 1995;32(4):295-302.

22. Tamborini E, Faccini S, Lidholm J, et al. Biochemical and Immunological Characterization of Recombinant Allergen Lol p 1. *European Journal of Biochemistry*. 1997;249(3):886-894.

23. Niederberger V, Laffer S, Froschl R, et al. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. *J Allergy Clin Immunol*. 1998;101(2 Pt 1):258-264.

24. Hew M, Lee J, Varese N, et al. Epidemic thunderstorm asthma susceptibility from sensitization to ryegrass (Lolium perenne) pollen and major allergen Lol p 5. *Allergy*. 2020.

25. Knox RB. Grass pollen, thunderstorms and asthma. *Clin Exp Allergy*. 1993;23(5):354-359.

26. O’Hehir RE, Varese NP, Deckert K, et al. Epidemic Thunderstorm Asthma Protection with Five-Grass Pollen Tablet Sublingual Immunotherapy: A Clinical Trial. *Am J Respir Crit Care Med*. 2018;198(1):126-128.

27. Müller U, Schmid-Grendelmeier P, Hausmann O, Helbling A. IgE to recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double sensitization from crossreaction in venom allergy. *Allergy*. 2012;67(8):1069-1073.

28. Müller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeberli G. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. *Allergy*. 2009;64(4):543-548.
29. Jakob T, Müller U, Helbling A, Spillner E. Component resolved diagnostics for hymenoptera venom allergy. *Current opinion in allergy and clinical immunology*. 2017;17(5):363-372.

30. Whitrow MJ, Moore VM, Rumbold AR, Davies MJ. Effect of supplemental folic acid in pregnancy on childhood asthma: a prospective birth cohort study. *American journal of epidemiology*. 2009;170(12):1486-1493.

31. Heeringa JJ, McKenzie CI, Varese N, et al. Induction of IgG2 and IgG4 B-cell memory following sublingual immunotherapy for ryegrass pollen allergy. *Allergy*. 2020;75(5):1121-1132.

32. Chan SK, Pomes A, Hilger C, et al. Keeping Allergen Names Clear and Defined. *Front Immunol*. 2019;10:2600.

33. Pomes A, Davies JM, Gadermaier G, et al. WHO/IUIS Allergen Nomenclature: Providing a common language. *Mol Immunol*. 2018;100:3-13.

34. Förster E, Dudlerb T, Gmachl M, Aberer W, Urbanek R, Suter M. Natural and recombinant enzymatically active or inactive bee venom phospholipase A2 has the same potency to release histamine from basophils in patients with Hymenoptera allergy. *Journal of Allergy and Clinical Immunology*. 1995;95(6):1229-1235.

35. Grobe K, Pöppelmann M, Becker W-M, Petersen A. Properties of group I allergens from grass pollen and their relation to cathepsin B, a member of the C1 family of cysteine proteinases. *European Journal of Biochemistry*. 2002;269(8):2083-2092.

36. Apostolou E, Deckert K, Puy R, et al. Anaphylaxis to Gelofusine confirmed by in vitro basophil activation test: a case series. *Anaesthesia*. 2006;61(3):264-268.

37. Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. *Leukemia*. 2012;26(9):1986-2010.

38. Edwards ESJ, Bosco JJ, Aui PM, et al. Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells. *Front Immunol*. 2019;10:2593.

39. Altmann F. The Role of Protein Glycosylation in Allergy. *International Archives of Allergy and Immunology*. 2007;142(2):99-115.

40. Halim A, Carlsson MC, Madsen CB, et al. Glycoproteomic analysis of seven major allergenic proteins reveals novel post-translational modifications. *Mol Cell Proteomics*. 2015;14(1):191-204.

41. Strasser R. Plant protein glycosylation. *Glycobiology*. 2016;26(9):926-939.

42. Rendj D, Wilson IBH, Paschinger K. The Glycosylation Capacity of Insect Cells. 2008.

43. Shi X, Jarvis DL. Protein N-glycosylation in the baculovirus-insect cell system. *Curr Drug Targets*. 2007;8(10):1116-1125.

44. Blank S, Michel Y, Seissmann H, et al. Evaluation of different glycoforms of honeybee venom major allergen phospholipase A2 (Api m 1) produced in insect cells. *Protein Pept Lett.* 2011;18(4):415-422.

45. Koren A, Lunder M, Molek P, et al. Fluorescent labeling of major honeybee allergens Api m 1 and Api m 2 with quantum dots and the development of a multiplex basophil activation test. *Allergy*. 2020;75(7):1753-1756.

46. Chirumbolo S, Vella A, Ortolani R, et al. Differential response of human basophil activation markers: a multi-parameter flow cytometry approach. *Clin Mol Allergy*. 2008;6:12.

47. Prussin C, Metcalfe DD. 5. IgE, mast cells, basophils, and eosinophils. *J Allergy Clin Immunol*. 2006;117(2 Suppl Mini-Primer):S450-456.

48. Knol EF. Requirements for effective IgE cross-linking on mast cells and basophils. *Molecular Nutrition & Food Research*. 2006;50(7):620-624.
49. Mukai K, Chinthrajah RS, Nadeau KC, Tsai M, Gaudenzio N, Galli SJ. A new fluorescent-avidin-based method for quantifying basophil activation in whole blood. *Journal of Allergy and Clinical Immunology*. 2017;140(4):1202-1206.e1203.

50. Sturm GJ, Kranzelbinder B, Sturm EM, Heinemann A, Groselj-Strele A, Aberer W. The basophil activation test in the diagnosis of allergy: technical issues and critical factors. *Allergy*. 2009;64(9):1319-1326.

51. Wagner N, Rudert M. Sensitivity and specificity of standardised allergen extracts in skin prick test for diagnoses of IgE-mediated respiratory allergies. *Clinical and Translational Allergy*. 2019;9(1):8.

Figures (n=6)

Hosted file

image1.emf available at [https://authorea.com/users/377513/articles/494167-cytobas-precision-component-resolved-diagnostics-for-allergy-using-flow-cytometric-staining-of-basophils-with-recombinant-allergen-tetramers](https://authorea.com/users/377513/articles/494167-cytobas-precision-component-resolved-diagnostics-for-allergy-using-flow-cytometric-staining-of-basophils-with-recombinant-allergen-tetramers)

**FIGURE 1.** Detection of allergen sensitization by quantifying binding of fluorescent allergen components of BV and RGP to basophils. A) Schematic diagram of DNA constructs for generation of the recombinant allergens Api m 1, Lol p 1 and Lol p 5. Recombinant allergens contained mutations to render the catalytic site inactive (Api m 1 H67Q, Lol p 1 H104V). Leader peptide and spacer (L); 6-histidine tag (His); avidin tag (AviTag). B) Western blots of recombinant allergens detected with anti-His antibody. C) Representative flow plot for detection of circulating basophils (CD123+IgE+) within gated mononuclear cells (Suppl Fig 1). D) Histograms depicting representative fluorescent staining of Api m 1, Lol p 1 and Lol p 5 tetramers on basophils from relevant allergic patients (red) and controls (blue). Values above the histograms represent median fluorescence intensity values of the population.

Hosted file

image2.emf available at [https://authorea.com/users/377513/articles/494167-cytobas-precision-component-resolved-diagnostics-for-allergy-using-flow-cytometric-staining-of-basophils-with-recombinant-allergen-tetramers](https://authorea.com/users/377513/articles/494167-cytobas-precision-component-resolved-diagnostics-for-allergy-using-flow-cytometric-staining-of-basophils-with-recombinant-allergen-tetramers)

**FIGURE 2.** Recombinant Api m 1 binds basophils from BV-allergic patients in a dose-dependent manner and induces basophil activation. A) Representative staining of basophils from blood of a BV-allergic patient stimulated with [Api m 1]4-APC (red) or streptavidin-APC (blue) - left plot. Median fluorescence intensity (MFI) of basophils from controls (blue; middle) and BV-allergic subjects (red; right) following incubation with 1 µg/ml streptavidin-APC (“0”) or 0.01, 0.1 and 1 µg/ml [Api m 1]4-APC. B) Representative histogram of CD63 staining on basophils (left), and frequencies of basophils from controls (middle) and BV-allergic patients (right) expressing CD63 following stimulation with streptavidin-APC or increasing concentrations of [Api m 1]4-APC. C) Representative histogram of CD63 staining on basophils (left), and frequencies of basophils from controls (middle) and BV-allergic patients (right) expressing CD63 following stimulation with increasing concentrations of BV extract.

Hosted file

image3.emf available at [https://authorea.com/users/377513/articles/494167-cytobas-precision-component-resolved-diagnostics-for-allergy-using-flow-cytometric-staining-of-basophils-with-recombinant-allergen-tetramers](https://authorea.com/users/377513/articles/494167-cytobas-precision-component-resolved-diagnostics-for-allergy-using-flow-cytometric-staining-of-basophils-with-recombinant-allergen-tetramers)

**FIGURE 3.** Recombinant Lol p 1 binds basophils from RGP-allergic patients in a dose-dependent manner and induces basophil activation. A) Left plot, representative staining of basophils from blood of a RGP-allergic patient stimulated with [Lol p 1]4-APC (red) or streptavidin-APC (blue). Median fluorescence intensity (MFI) of basophils from controls (blue; middle) and RGP-allergic subjects
(red; right) following incubation with $1 \mu g/ml$ streptavidin-APC (“0”) or 0.01, 0.1 and $1 \mu g/ml$ [Lol p 1]$_4$-APC. B) Representative histogram of CD63 staining on basophils (left), and frequencies of basophils from controls (middle) and RGP-allergic patients (right) expressing CD63 following stimulation with streptavidin-APC or increasing concentrations of [Lol p 1]$_4$. C) Representative histogram of CD63 staining on basophils (left), and frequencies of basophils from controls (middle) and RGP-allergic patients (right) expressing CD63 following stimulation with increasing concentrations of RGP extract.

Hosted file

image4.emf available at https://authorea.com/users/377513/articles/494167-cytobas-precision-component-resolved-diagnostics-for-allergy-using-flow-cytometric-staining-of-basophils-with-recombinant-allergen-tetramers

FIGURE 4. Sensitivity and specificity of BAT and CytoBas for allergy. A) Frequencies of CD63$^+$ basophils following in vitro stimulation with [Api m 1]$_4$ (left) and receiver operator characteristics (ROC) curve of CD63 positivity (right). For each individual the highest frequency was selected from the serial dilutions in Fig 2B. B) Frequencies of CD63$^+$ basophils following in vitro stimulation with [Lol p 1]$_4$ and ROC curve of CD63 positivity (right). For each individual the highest frequency was selected from the serial dilutions in Fig 3B. C) Staining intensities as ratio of [Api m 1]$_4$-APC/streptavidin-APC on basophils (left) and ROC curve of [Api m 1]$_4$ staining intensity (right). D) Staining intensities as ratio of [Lol p 1]$_4$-APC/streptavidin-APC on basophils (left) and ROC curve of [Lol p 1]$_4$ staining intensity (right). Statistics for CD63$^+$ frequencies and allergen tetramer stains, Mann-Whitney U-test; for ROC curves, Wilson/Brown method to test whether the confidence level of the outcome distribution is greater than 95%. **** $p < 0.0001$.

Hosted file

image5.emf available at https://authorea.com/users/377513/articles/494167-cytobas-precision-component-resolved-diagnostics-for-allergy-using-flow-cytometric-staining-of-basophils-with-recombinant-allergen-tetramers

FIGURE 5. Multiplex flow cytometry using multiple allergen tetramers in a single tube as a component-resolved diagnostic test for allergy. A, B) Representative histograms of basophils from a control (blue) or RGP-allergic patient (red) stained with Lol p 1 and Lol p 5 tetramers in a single tube. C) 2D dot plot of Lol p 1 and Lol p 5 tetramer staining of the basophils from the control and patient in panels A and B. D) Scatterplot depicting MFI ratios of allergen:streptavidin for [Lol p 1]$_4$-APC vs strep-APC and [Lol p 5]$_4$-BV711 vs strep-BV711 on basophils from controls (blue, n = 10) and RGP-allergic subjects (red, n=15) stained with both allergen tetramers or both streptavidin conjugates in a single tube.

Hosted file

image6.emf available at https://authorea.com/users/377513/articles/494167-cytobas-precision-component-resolved-diagnostics-for-allergy-using-flow-cytometric-staining-of-basophils-with-recombinant-allergen-tetramers

FIGURE 6. Multiplex flow cytometry distinguishes between different allergic sensitizations with a single tube. A) Representative histograms of [Lol p 1]$_4$, [Lol p 5]$_4$ or [Api m 1]$_4$ MFI on pDCs (blue) and basophils (red) from thawed PBMC of control, BV-allergic and RGP-allergic patients. Numbers accompanying histograms denote MFI (non-bolded indicate pDCs; bolded indicate basophils). Scatterplots depicting correlation between serum levels of allergen-specific IgE and MFI of allergen tetramers on basophils stained with B) Api m 1 C) Lol p 1 and D) Lol p 5 allergen tetramers. AU, arbitrary units. Significance and r-squared ($r^2$) of correlation determined by linear regression.